UAWJ248
UAWJ248 is a SARS-CoV-2 main protease (Mpro) inhibitor with an IC50 of 0.012 μM. UAWJ248 inhibits activity via initial reversible binding followed by irreversible inactivation. UAWJ248 inhibits SARS-CoV-2 replication and can be used for the research of SARS-CoV-2 infection.
For research use only. We do not sell to patients.
- CAS No.: 2589736-94-5
- Formula: C31H45N5O7
- Molecular Weight:599.72
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero C1008 | EC50 |
11.1 μM
Compound: 62; UAWJ248
|
Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in Vero E6 cells assessed as reduction in viral replication incubated for 3 days by viral plaque assay
Antiviral activity against SARS-CoV-2 USA-WA1/2020 infected in Vero E6 cells assessed as reduction in viral replication incubated for 3 days by viral plaque assay
|
[PMID: 37244162] |
In Vitro
UAWJ248 potently inhibits tag-free native SARS-CoV-2 Mpro with an IC50 of 0.012 µM and shows IC50 >20 μM for PLpro[1].
UAWJ248 (0.01-100 µM; 48 h) inhibits SARS-CoV-2 replication in Vero E6 cells with an EC50 of 20.49 µM[1].
UAWJ248 (0.01-100 µM) inhibits SARS-CoV-2 replication in Vero E6 cells with an EC50 of 11.1 µM in the plaque assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Vero E6 cells
-
Concentration:100 µM, 33 µM, 11 µM, 3.7 µM, 1.1 µM
-
Incubation Time:48 h post-infection
-
Result:Inhibited SARS-CoV-2 replication in a dose-dependent manner, with an EC50 of 20.49 µM.
Chemical Information
-
CAS No. 2589736-94-5
-
Molecular Weight 599.72
-
Formula C31H45N5O7
-
SMILES
O=C(NCC1)[C@@H]1C[C@@H](C(C(NC2CC2)=O)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC(OCC3=CC=CC=C3)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)